B-cell acute lymphoblastic leukemia
Clinical trials for B-cell acute lymphoblastic leukemia explained in plain language.
Never miss a new study
Get alerted when new B-cell acute lymphoblastic leukemia trials appear
Sign up with your email to follow new studies for B-cell acute lymphoblastic leukemia, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a Chemo-Antibody combo beat a tough leukemia?
Cure Stopped earlyThis phase II trial is testing whether adding the targeted antibody-drug inotuzumab ozogamicin to a standard chemotherapy regimen (Hyper-CVAD) improves outcomes for adults with B-cell acute lymphoblastic leukemia. The study enrolls people with newly diagnosed or recently remitted…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Cure
Last updated Aug 01, 2026 00:00 UTC
-
Engineered immune cells take aim at leukemia that evades standard therapy
Disease control Stopped earlyThis trial investigates a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia (B-ALL) whose cancer has stopped responding to anti-CD19 treatment. The therapy uses a patient's own immune cells, modified to target several other markers on leukemia cel…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New combo therapy aims to wipe out leukemia cells for good
Disease control Stopped earlyThis early-stage trial tests a combination therapy for B-cell acute lymphoblastic leukemia (B-ALL). It uses specially engineered immune cells (CAR-T cells and CTLs) followed by a dendritic cell vaccine to target multiple cancer markers. The goal is to achieve a very deep remissio…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase 1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New immune cell therapy targets Hard-to-Treat leukemia in early trial
Disease control Stopped earlyThis early-phase trial tests a new treatment called CD19 t-hANK for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back after previous treatments. The therapy uses specially designed immune cells to attack cancer cells. Up to 10 participant…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase 1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Experimental blood cancer drug trial halted early
Disease control Stopped earlyThis study tested a new drug called SAR443579 in adults and children with certain blood cancers that had come back or not responded to treatment. The goal was to see if the drug was safe and could shrink or control the cancer. The trial was stopped early, so results are limited.
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase 1/2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Targeted drug combo shows promise in blood cancer transplant study
Disease control Stopped earlyThis study tested whether adding the targeted drug inotuzumab ozogamicin before and after a stem cell transplant could help control leukemia and lymphoma. It included 15 people aged 12 to 75 with certain blood cancers. The study was stopped early, but researchers looked at safety…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Engineered immune cells take aim at Tough-to-Treat leukemia
Disease control Stopped earlyThis early-phase study tested a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia that returned or didn't respond to standard treatments. The therapy used the patient's own immune cells, modified to target two markers (CD19 and CD20) on leukemi…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase 1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
CRISPR-Tweaked donor cells take on Hard-to-Treat blood cancers
Disease control Stopped earlyThis study tested a new treatment called CTX110 for people with B-cell blood cancers that came back or didn't respond to standard therapy. CTX110 uses donor immune cells that are edited with CRISPR technology to target and attack cancer cells. The trial enrolled 93 adults and aim…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase 1/2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC